NMDP Launches Minority Cord Blood Recruitment Initiative

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

MINNEAPOLIS-Give Life Twice. That’s the message behind a new National Marrow Donor Program (NMDP) pilot project designed to increase the number of minority umbilical cord blood units listed on the NMDP Registry. Patients of minority race and ethnicity are less likely than Caucasians to find a matched donor in the Registry, the NMDP said in a press release. The NMDP’s goal is to collect 2,000 units of cord blood from African-American, Hispanic/Latino, and Asian/Pacific Islander donors.

MINNEAPOLIS—Give Life Twice. That’s the message behind a new National Marrow Donor Program (NMDP) pilot project designed to increase the number of minority umbilical cord blood units listed on the NMDP Registry. Patients of minority race and ethnicity are less likely than Caucasians to find a matched donor in the Registry, the NMDP said in a press release. The NMDP’s goal is to collect 2,000 units of cord blood from African-American, Hispanic/Latino, and Asian/Pacific Islander donors.

Four NMDP Cord Blood Banks are participating in the project: Bonfils Cord Blood Services, collecting units in Denver, Boulder, and Colorado Springs, Colorado; Children’s Hospital of Orange County Cord Blood Bank, collecting units in Orange County, California; LifeCord, collecting units in Montgomery, Alabama and Gainesville, Florida; and St. Louis Cord Blood Bank, collecting units in the greater St. Louis, Missouri area.

Related Videos
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Video 1 - 4 KOLs are featured in "Triaging and Prioritizing Patients with Multiple Myeloma"
Video 1 - 4 KOLs are featured in "CAR T-Cell Therapy: Leukapheresis Practices"
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Investigators must continue to explore the space for lisocabtagene maraleucel in mantle cell lymphoma, according to Manali Kamdar, MD.
Related Content